Draft Evidence Summary: Aspirin to Prevent Cardiovascular Disease
Draft Evidence Review for Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication
This opportunity for public comment expired on October 12, 2015 at 8:00 PM EST
Note: This is a Draft Evidence Review. This draft is distributed solely for the purpose of receiving public input. It has not been disseminated otherwise by the USPSTF. The final Evidence Review will be used to inform the USPSTF Recommendation Statement on this topic.
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
In the interest of seeking feedback on the most current evidence available and providing all the evidence considered in its deliberation, the USPSTF is posting three Evidence Summaries for public comment and providing three Evidence Reviews and a Modeling Report as additional background information. While the systematic evidence reviews provide comprehensive details on the approach and the majority of the evidence, the Evidence Summaries provide the most up-to-date evidence. Therefore, the USPSTF is posting the Evidence Summaries for public comment. Evidence Summaries are manuscripts derived from the review that will be published in a peer-reviewed journal.
Draft: Draft Evidence Summary
Internet Citation: Draft Evidence Review: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication. U.S. Preventive Services Task Force. September 2015.